Boston Scientific (BSX) Gains from Investment Securities (2020 - 2026)

Boston Scientific has disclosed Gains from Investment Securities across 7 years of filings, most recently posting -$16.0 million for Q2 2026.

• In Q2 2026, Gains from Investment Securities fell 220.0% year-over-year to -$16.0 million; the TTM figure through Jun 2026 stood at -$28.0 million (down 16.67% YoY), while the FY2025 annual figure was $18.0 million, up 460.0% from the prior year.
• Gains from Investment Securities came in at -$16.0 million for Q2 2026 at Boston Scientific, up from -$30.0 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $36.0 million in Q2 2022 to a low of -$33.0 million in Q4 2022.
• Average Gains from Investment Securities over 5 years is $3.3 million, with a median of $9.0 million recorded in 2025.
• Year-over-year, Gains from Investment Securities soared 800.0% in 2025 and plunged 700.0% in 2026.
• Over 5 years, Gains from Investment Securities stood at -$33.0 million in 2022, then jumped by 145.45% to $15.0 million in 2023, then sank by 106.67% to -$1.0 million in 2024, then soared by 800.0% to $7.0 million in 2025, then sank by 328.57% to -$16.0 million in 2026.
• Per Business Quant data, the three most recent Gains from Investment Securities figures were -$16.0 million in Q2 2026, -$30.0 million in Q1 2026, and $7.0 million in Q4 2025.